{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:40:31Z","timestamp":1789645231087,"version":"4.0.0"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The United States Food and Drug Administration (FDA) approved Vemurafenib in August 2011, for treatment of melanoma with BRAF V600 mutation. It has shown improvement in the median overall survival of melanoma patients. The most common adverse effects of vermurafenib are arthralgia, rash, alopecia, photosensitivity and fatigue. Other infrequent and severe adverse reactions reported in patients include keratocanthomas, hypersensitivity, Stevens Johnson Syndrome, toxic epidermal necrolysis, uveitis, QT prolongation, and hepatotoxicity. We hereby present a case of bilateral facial palsy as an adverse effect of vemurafenib therapy, seen after six weeks of commencement of the drug. Complete resolution of the symptoms was seen when the patient was taken off vemurafenib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.132339","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T05:34:29Z","timestamp":1399959269000},"page":"187-188","source":"Crossref","is-referenced-by-count":17,"title":["Vemurafenib-induced bilateral facial palsy"],"prefix":"10.4103","volume":"60","author":[{"given":"FNU","family":"Shailesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LF","family":"Hutchins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20240205","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl Med"},{"key":"R2-13-20240205","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl Med"},{"key":"R3-13-20240205","first-page":"458371","article-title":"Bilateral facial nerve palsy: A diagnostic dilemma","volume":"2012","author":"Pothiawala","year":"2012","journal-title":"Case Rep Emerg Med"},{"key":"R4-13-20240205","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0364-7722(81)90024-2","article-title":"Clinical detection and assessment of drug induced neurotoxicity","volume":"5","author":"Naranjo","year":"1981","journal-title":"Prog Neuropsychopharmacol"},{"key":"R5-13-20240205","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/0192623311410442","article-title":"RAF inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat","volume":"39","author":"Wisler","year":"2011","journal-title":"Toxicol Pathol"},{"key":"R6-13-20240205","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1200\/JCO.2012.45.7028","article-title":"Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma","volume":"31","author":"Klein","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201460020-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:56:34Z","timestamp":1786647394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201460020-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.132339","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}